P1141: ENCOURAGING COMPLETE RESPONSES (CRS) OBSERVED WITH CDK9 INHIBITOR AZD4573 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL): EARLY TRIAL ANALYSIS

• Jake Shortt,
• Tatyana Feldman,
• Graham Collins,
• Jasmine Zain,
• Amit Khot,
• Jin Seok Kim,
• Franck Morschhauser,
• Tae Min Kim,
• Justine Roderick,
• Jeong Lim Yoon,
• Shringi Sharma,
• Jamal Saeh,
• Jiale Dai,
• Ruben Reyes,
• Richardp Olsson,
• Pier Luigi Zinzani

Affiliations

Jake Shortt

1 Monash University & Monash Health, Melbourne, Australia

Tatyana Feldman

2 Hackensack University Medical Center, Hackensack, United States

Graham Collins

3 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Jasmine Zain

4 City of Hope, Duarte, United States

Amit Khot

5 Peter MacCallum Cancer Centre, Victoria, Australia

Jin Seok Kim

6 Yonsei University, Seoul, Korea, Rep. of South

Franck Morschhauser

7 CHRU Lille, Hôpital Claude Huriez, Lille, France

Tae Min Kim

8 Seoul University National Hospital, Seoul, Korea, Rep. of South

Justine Roderick

9 AstraZeneca, Boston, United States

Jeong Lim Yoon

9 AstraZeneca, Boston, United States

Shringi Sharma

10 AstraZeneca, South San Francisco, United States

Jamal Saeh

9 AstraZeneca, Boston, United States

Jiale Dai

11 AstraZeneca, Waltham, United States

Ruben Reyes

9 AstraZeneca, Boston, United States

Richardp Olsson

12 AstraZeneca, Gothenburg, Sweden

Pier Luigi Zinzani

13 University of Bologna Institute of Hematology, Bologna, Italy